SCHEMBL4907342

SCHEMBL4907342

Nc1nc(N)c(-c2ccccc2)c(OCCN2CCOCC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.56
ADORA1 P30542 5/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADORA2B P29275 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KDM4E B2RXH2 1/20 0.47
BCHE P06276 1/20 0.47
MAOA P21397 1/20 0.47
ACHE P22303 1/20 0.47
MAOB P27338 1/20 0.47
LTA4H P09960 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HIF1A Q16665 1/20 0.46
TNK2 Q07912 1/20 0.45
DRD1 P21728 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913524 0.94 ADORA2A (0.50) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL4907739 0.80 HRH3 (0.48) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL1644546 0.75 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL4907346 0.75 ADORA2A (0.41) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL4913532 0.74 DHFR (0.44) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL3334078 0.73 KMT2A (0.48) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL3339040 0.72 ALDH1A1 (0.48) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL1830502 0.72 ADORA2A (1.00) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL3338187 0.71 MEN1 (0.47) ADORA2AADORA1ADORA3ADORA2BMEN1
SCHEMBL3337374 0.71 MEN1 (0.47) ADORA2AADORA1ADORA3ADORA2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349859-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2013-01-08 US disclosed
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration CCND2, KDR, FLT4 ADORA2A 560/4885ADORA1 680/4885ADORA3 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.